BrightGene Bio-Medical Technology Co. Ltd. Class A
SSSE:68816630.70
CNY
-1.35
(-4.21%)
ISIN
CNE100003PR1
Return %
Stock
S&P 500
1Y
-41.62
14.20
3Y
-20.47
81.12
5Y
-1.70
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jian Dong Yuan
- Full Time Employees
- 1,196
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Suzhou China
- IPO Date
- Oct 31, 2019
- Website
- bright-gene.com
- Similar Companies
- Business
- BrightGene Bio-Medical Technology Co., Ltd. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of complex active pharmaceutical ingredients (APIs), key pharmaceutical intermediates, finished dosage formulations, and innovative chemical and biological therapeutics. Founded in 2001 and headquartered in Suzhou, China, the company operates across the global pharmaceutical and healthcare sectors, supplying generic drug manufacturers, biotechnology companies, and healthcare providers across domestic and international markets, including the United States, the European Union, Japan, and South Korea. The company organizes its business operations into specialized pharmaceutical development, API manufacturing, finished formulation production, and contract development and manufacturing organization (CDMO) services. Its primary product and service offerings comprise high-barrier active pharmaceutical ingredients and finished dosage forms across several major therapeutic categories: antifungal agents, including caspofungin acetate, micafungin sodium, and anidulafungin; antineoplastic and oncology drugs, including eribulin mesylate, cabazitaxel, bortezomib, and regorafenib; antiviral therapies, including oseltamivir phosphate, entecavir, and tenofovir derivatives; cardiovascular and anticoagulant agents, including fondaparinux sodium and apixaban; immunosuppressant and dermatological treatments, including pimecrolimus and voclosporin; complex injectable formulations and inhalation suspensions; and integrated CDMO, technology licensing, process development, and regulatory support services delivered through subsidiaries such as BrightGene (Taixing) Pharmaceutical Co., Ltd., Changshu Boyuan Pharmaceutical Co., Ltd., and BrightGene (Hainan) Pharmaceutical Co., Ltd. In recent strategic developments, BrightGene Bio-Medical Technology Co., Ltd. has expanded its focus from complex generic APIs toward proprietary innovative biopharmaceuticals, highlighted by the clinical advancement of BGM0504, an investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist undergoing mid-to-late-stage clinical trials for the treatment of type 2 diabetes mellitus and chronic weight management. The company has also expanded its clinical pipeline in respiratory inhalation therapies and targeted drug delivery conjugates, scaled its high-potency active pharmaceutical ingredient (HPAPI) and peptide manufacturing infrastructure, and strengthened international distribution partnerships and regulatory filings with global authorities, including the United States Food and Drug Administration and European regulatory agencies, to support global commercialization of its formulation portfolio.